Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities

Significant components of Delek's continuing operations deferred tax assets (liabilities) reported in the accompanying consolidated financial statements as of December 31, 2024 and 2023 were as follows (in millions):

	December 31,
	2024		2023
Non-Current Deferred Taxes:
Property, plant and equipment, and intangibles	$	(237.4)	$	(266.2)
Right-of-use asset	(23.7)		(32.8)
Partnership and equity investments	(188.2)		(196.7)
Total deferred tax liabilities	(449.3)		(495.7)
Interest expense limitation under 163j	112.7		71.6
Compensation and employee benefits	10.3		16.6
Net operating loss carryforwards	134.8		125.7
Tax credit carryforwards	11.3		5.8
Deferred revenues	15.7		18.7
Lease obligation	27.7		37.7
Reserves and accruals	10.5		34.7
Derivatives and hedging	0.8		1.4
Inventories	1.0		2.7
Other	(3.8)		—
Total deferred tax assets	321.0		314.9
Valuation allowance	(86.5)		(83.3)
Total net deferred tax liabilities	$	(214.8)	$	(264.1)

Schedule of Effective Income Tax Rate Reconciliation

The difference between the actual income tax expense and the tax expense computed by applying the statutory federal income tax rate to income was attributable to the following (in millions):

	Year Ended December 31,
	2024		2023		2022
Provision (benefit) for federal income taxes at statutory rate	$	(148.2)	$	3.5	$	67.6
State income tax benefit, net of federal tax provision	(3.9)		(3.9)		(15.7)
Income tax benefit attributable to non-controlling interest	(8.6)		(6.4)		(7.2)
Tax credits and incentives (1)	(4.7)		(9.6)		(6.9)
Non-deductible goodwill	44.6		—		—
Changes in valuation allowance	3.2		10.3		14.0
Revaluation related to state legislative changes	0.7		(2.5)		—
Impact of stock compensation	2.5		1.6		0.9
Impact of officer's compensation	1.7		3.2		3.2
Other items	4.8		0.8		0.5
Income tax expense (benefit)	$	(107.9)	$	(3.0)	$	56.4

(1)     Tax credits and incentives include work opportunity and research and development credits, as well as incentives for the Company’s biodiesel blending operations.

Schedule of Components of Income Tax Expense (Benefit)

Income tax expense (benefit) was as follows (in millions):

	Year Ended December 31,
	2024		2023		2022
Current	$	(4.3)	$	(1.4)	$	(5.2)
Deferred	(103.6)		(1.6)		61.6
	$	(107.9)	$	(3.0)	$	56.4

Schedule of Unrecognized Tax Benefits Roll Forward

Increases and decreases to unrecognized tax benefits, which includes interest and penalties, were as follows (in millions):

	Year Ended December 31,
	2024		2023		2022
Balance at the beginning of the year	$	10.9	$	7.0	$	14.1
Additions based on tax positions related to current year	0.2		4.3		0.9
Additions for tax positions related to prior years and acquisitions	0.4		0.2		0.1
Reductions for tax positions related to prior years	(0.1)		(0.2)		(6.5)
Reductions for tax positions related to lapse of applicable statute of limitations	(4.5)		(0.4)		(0.4)
Reductions for tax positions related to settlements with taxing authorities	—		—		(1.2)
Balance at the end of the year	$	6.9	$	10.9	$	7.0